
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd is positioned positively due to its innovative drug candidate Brepocitinib, which demonstrates a substantial improvement in efficacy with a mean total improvement score (TIS) of 46.5, significantly surpassing expectations and meeting high investor standards. The convenient once-daily (QD) dosing of Brepocitinib offers a clear advantage over the current infusion therapy, IVIg, which has considerable sales of approximately $500 million but involves cumbersome administration for patients. Additionally, the company's diverse pipeline, including promising candidates like VTAMA for psoriasis, further enhances its growth potential in the biopharmaceutical market.
Bears say
Roivant Sciences has faced multiple significant setbacks in its clinical trials, including failures of its drug candidates IMVT, brepocitinib, and mosliciguat, which could undermine investor confidence and stall the company's growth trajectory. These failures reflect a broader trend of lackluster performance in the development pipeline, suggesting potential challenges in bringing successful treatments to market. Consequently, the company's current valuation may not be supported by its future revenue prospects, leading to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares